

JS005424447A

United States Patent [19]

Griffith et al.

[11] Patent Number:

5,424,447

[45] Date of Patent:

Jun. 13, 1995

[54] HEME BINDING COMPOUNDS AND USE sion, Biol. N THEREOF 2-4.

[75] Inventors: Owen W. Griffith, Milwaukee;

Krishnaswamy Narayanan, Wauwatosa, both of Wis.

[73] Assignee: The Medical College of Wisconsin

Research Foundation, Inc.,

Milwaukee, Wis.

[21] Appl. No.: 87,371

[22] Filed: Jul. 7, 1993

[51] Int. Cl.6 C07D 333/12; C07C 321/02;

C07C 229/26 [52] **U.S. Cl.549/74;** 562/557;

562/560; 549/76 [58] **Field of Search** 562/556, 557, 555;

514/562; 549/74, 76, 78

[56] References Cited

U.S. PATENT DOCUMENTS

3,637,837	1/1972	Fujimoto et al 562/556
3,798,269	3/1974	Cutler et al 564/59
4,438,204	3/1984	Deeg et al 436/67
4,568,640	2/1986	Rubin 435/70
5,028,627	7/1991	Kilbourn 514/565
5,059,624	10/1991	Monache et al 514/616
5,059,712	10/1991	Griffith 562/560
5,115,100	5/1992	Wu et al 530/385
5,133,866	7/1992	Kauvar 210/635
5,158,883	10/1992	Griffith 435/240.2
5,196,195	3/1993	Griffith 424/94.6
5,216,025	6/1993	Gross et al 514/565
5,246,971	9/1993	Williamson et al 514/634
5,266,594	11/1993	Dawson et al 514/560
5,281,627	1/1994	Griffith 514/565
5,286,739	2/1994	Kilbourn et al 514/400
5,296,466	3/1994	Kilbourn et al 514/6

FOREIGN PATENT DOCUMENTS

1096894 1/1961 Germany . 1804894 8/1969 Germany .

OTHER PUBLICATIONS

Adnot et al, Loss of Endothelium-Dependent Relaxation During Chronic Hypoxic Pulmonary Hyperten-

sion, Biol. Nitric Oxide, Proc. Int. Meet 1991, vol. 1-3-2-4.

Keiichi et al, Effect of Systemic L-Arginine Administration on Hemodyamics and Nitric Oxide Release, Jpn. Heart J., 33(1), 41-8, 1992.

(List continued on next page.)

Primary Examiner—Glennon H. Hollrah Assistant Examiner—Deborah Lambkin

[57] ABSTRACT

Inhibitors of nitric oxide formation from arginine useful for treating hypotension, inflammation, stroke and to restore vascular contractile sensitivity to the effects of α_1 adrenergic agonists are physiologically active compounds including N^δ -substituted ornithine or N^ε -substituted lysine moieties or monoalkyl carbon-substituted N^δ -substituted ornithine or N^ε -substituted lysine moieties, having the formula

wherein R is $(CH_2)_yCH_3$ or H, R' is CH_2 or C(H) $(CH_2)_yCH_3$, and R" is CH_2 or C(H) $(CH_2)_yCH_3$, with y ranging from 0 to 5, and x is 0 or 1 and wherein none or only one of R, R' and R" provides an alkyl substituent on ornithine or lysine moiety, and wherein Q is a heme binding moiety and/or a sulfur-containing binding moiety and Q' is —NH₂ when there is a double bond between the omega carbon and Q and Q' is —NH when there is a single bond between the omega carbon and Q, and physiologically acceptable acid addition salts thereof.

23 Claims, 5 Drawing Sheets